Recombinant activated factor VII in cardiac surgery: single-center experience

Abstract

Background

the widespread off-label use of recombinant activated factor VII for the control of refractory postoperative hemorrhage continues despite a warning from the Food and Drug Administration. Although effective in reducing the need for transfusion of blood and blood products, safety concerns still prevail.

Objective

to compare the dosing and efficacy of recombinant activated factor VII between pediatric and adult patients, and in the operating room and intensive care unit.

Methods

the records of 69 patients (33 children and 36 adults) who underwent cardiovascular surgery and received recombinant activated factor VII were reviewed retrospectively. The dose of recombinant activated factor VII, mediastinal drainage, use of blood and blood products, incidence of thrombosis, and 28-day mortality were studied.

Results

the efficacy of recombinant activated factor VII was comparable in adults and children, despite the lower dose in adults. Prophylactic use of recombinant activated factor VII decreased the incidence of mediastinal exploration and the duration of intensive care unit stay. A 4.3% incidence of thrombotic complications was observed in this study.

Conclusion

the efficacious dose of recombinant activated factor VII is much less in adults compared to children. Prophylactic use of recombinant activated factor VII decreases the dose required, the incidence of mediastinal exploration, and intensive care unit stay, with no survival benefit.

Keywords

Blood loss surgical Cardiac surgical procedures Factor VIIa Postoperative hemorrhage Recombinant proteins

Get full access to this article

View all access options for this article.

References

Highlights of Prescribing Information. Available at: http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm089232.htm. Accessed November 28, 2012.

Kim

Son

. The prophylactic use of recombinant factor VIIa in a patient with DeBakey type III aortic dissection. A case report. Korean J Anesthesiol 2011; 61: 431–434.

Warren

Mandal

Hadjianastassiou

. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 2007; 83: 707–714.

Hacquard M, Durand M, Lecompte T, Boini S, Briançon S, Carteaux JP. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7). Eur J Cardiothorac Surg 2011; 40: 1320–1327.

McQuilten

Barnes

Zatta

Phillips

Haemostasis Registry Steering Committee . Off-label use of recombinant factor VIIa in pediatric patients. Pediatrics 2012; 129: e1533–1540.

Winch PD, Naguib AN, Bradshaw JR, Galantowicz M, Tobias JD. Decreasing the need for transfusion: infant cardiac surgery using hemodilution and recombinant factor VIIa. Pediatr Cardiol. Epub ahead of print 4 July 2012.

Diprose

Herbertson

O’Shaughnessy

Gill

. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95: 596–602.

Chuansumrit

Teeraratkul

Wanichkul

. Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients. Blood Coagul Fibrinolysis 2010; 21: 354–362.

Kylasam

Mos

Fijtin

Webster

Chard

Egan

. Recombinant activated factor VII following pediatric cardiac surgery. J Intensive Care Med 2009; 24: 116–121.

10.

Dinardo

Physiology and techniques of extracorporeal circulation in the pediatric patient. In: Lake

Booker

editors (eds). Pediatric Cardiac Anesthesia, 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2005, pp. 240–240.

11.

Karkouti

Levy

. Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. Anesth Analg 2011; 113: 711–712.

12.

Hedner

. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747–757.

13.

Brummel-Ziedins

Orfeo

Jenny

Everse

Mann

Blood coagulation and fibrinolysis. In: Greer

Forester

Rodgers

Paraskevas

Glader

(eds). Wintrobe’s Clinical Hematology, 12th ed. Philadelphia: Lippincott Williams and Wilkins, 2009, pp. 543–543.

14.

Karsies

Nicol

Galantowicz

Stephens

Kerlin

. Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience. Ann Thorac Surg 2010; 89: 570–576.

15.

Agarwal

Bennett

Churchwell

. Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 2007; 84: 161–169.

16.

Singh

Chauhan

Choudhary

Vasdev

Talwar

. Recombinant activated factor VII for hemorrhage after pediatric cardiac surgery. Asian Cardiovasc Thorac Ann 2012; 20: 19–23.

17.

Warren OJ, Rogers PL, Watret AL, et al. Defining the role of recombinant activated factor VII in pediatric cardiac surgery: where should we go from here [Review]? Pediatr Crit Care Med 2009; 10: 572–82.

18.

Goodnough

Lublin

Zhang

Despotis

Eby

. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44: 1325–1331.

19.

Novo Nordisk Inc. Novoseven@RT (package insert). Denmark: Novo Nordisk, Inc., 2012.

20.

Oliver

Hemostasis, coagulation, and transfusion in the pediatric cardiac patient. In: Lake

Booker

editors (eds). Pediatric Cardiac Anesthesia, 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2005, pp. 314–314.